JNJ · NYSE · CIK 0000200406

JOHNSON & JOHNSON

JOHNSON & JOHNSON’s most recent SEC filing in our snapshot is a Form 13F-HR filed on Oct 26, 2026. In fiscal 2025 (year ended Dec 28, 2025) it reported revenue of $94.2B and net income of $26.8B, according to its XBRL data on EDGAR. Its EDGAR record lists 64 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
$94.2B
Net income, FY2025
$26.8B
Form 4 filings on record, past 12 months
64

Company overview

Legal name (as filed)
JOHNSON & JOHNSON
Ticker
JNJ
SEC Central Index Key (CIK)
0000200406
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
NEW BRUNSWICK, NJ
State or country of incorporation
NJ
Fiscal year ends
January 3
SEC filer category
Large accelerated filer
Position in SEC ticker list
#17 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from JOHNSON & JOHNSON’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.

Revenue
$78.7BFY2022$80.0BFY2023$85.2BFY2023$88.8BFY2024$94.2BFY2025
Net income
$20.9BFY2022$17.9BFY2023$35.2BFY2023$14.1BFY2024$26.8BFY2025
JNJ annual results
ItemFY2022
ended Jan 2, 2022		FY2023
ended Jan 1, 2023		FY2023
ended Dec 31, 2023		FY2024
ended Dec 29, 2024		FY2025
ended Dec 28, 2025
Revenue$78.7B$80.0B$85.2B$88.8B$94.2B
Net income$20.9B$17.9B$35.2B$14.1B$26.8B
Diluted EPS$7.81$6.73$13.72$5.79$11.03
Total assets$182.0B$187.4B$167.6B$180.1B$199.2B
Cash and equivalents$14.5B$12.9B$21.9B$24.1B$19.7B

XBRL tags used: revenue = RevenueFromContractWithCustomerExcludingAssessedTax; netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

JNJ latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Feb 11, 202610-KAnnual report· period Dec 28, 2025Document · Index
Oct 21, 202610-QQuarterly report· period Sep 27, 2026Document · Index
Oct 13, 20268-KResults of operations· period Oct 13, 2026Document · Index
Mar 11, 2026DEF 14ADefinitive proxy statement· period Mar 11, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about JOHNSON & JOHNSON, by form type:

4 ×16144 ×78-K ×613F-HR ×310-Q ×211-K ×23 ×1N-PX ×1SD ×1SCHEDULE 13G ×1
JNJ recent filings
FiledFormWhat it isOriginal
Oct 26, 202613F-HRInstitutional investment manager holdings report· period Sep 30, 2026Document · Index
Oct 21, 202610-QQuarterly report· period Sep 27, 2026Document · Index
Oct 13, 20268-KResults of operations· period Oct 13, 2026Document · Index
Sep 10, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 8, 2026Document · Index
Sep 10, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 8, 2026Document · Index
Sep 10, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 8, 2026Document · Index
Sep 4, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 2, 2026Document · Index
Sep 2, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 1, 20263Initial statement of beneficial ownership· period Sep 1, 2026Document · Index
Aug 18, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 17, 2026Document · Index
Aug 17, 2026144Notice of proposed sale of securitiesDocument · Index
Aug 14, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 13, 2026Document · Index
Aug 13, 2026144Notice of proposed sale of securitiesDocument · Index
Aug 11, 2026N-PXN-PX· period Jun 30, 2026Document · Index
Aug 7, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 5, 2026Document · Index
Aug 7, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 6, 2026Document · Index
Aug 6, 2026144Notice of proposed sale of securitiesDocument · Index
Aug 6, 202613F-HRInstitutional investment manager holdings report· period Jun 30, 2026Document · Index
Aug 5, 2026144Notice of proposed sale of securitiesDocument · Index
Aug 4, 20268-KDirector or officer change· period Aug 4, 2026Document · Index
Jul 29, 20268-KRegulation FD disclosure· period Jul 29, 2026Document · Index
Jul 28, 20268-KRegulation FD disclosure· period Jul 27, 2026Document · Index
Jul 23, 202610-QQuarterly report· period Jun 28, 2026Document · Index
Jul 21, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 20, 2026Document · Index
Jul 20, 2026144Notice of proposed sale of securitiesDocument · Index
Jul 15, 20268-KResults of operations· period Jul 15, 2026Document · Index
Jun 25, 202611-KAnnual report of employee stock plans· period Dec 31, 2025Document · Index
Jun 25, 202611-KAnnual report of employee stock plans· period Dec 31, 2025Document · Index
Jun 12, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 11, 2026Document · Index
Jun 11, 2026144Notice of proposed sale of securitiesDocument · Index
Jun 11, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 9, 2026Document · Index
Jun 11, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 9, 2026Document · Index
Jun 11, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 9, 2026Document · Index
May 27, 2026SDSpecialized disclosure report (conflict minerals)Document · Index
May 13, 202613F-HRInstitutional investment manager holdings report· period Mar 31, 2026Document · Index
May 4, 20264Statement of changes in beneficial ownership (insider trade)· period May 1, 2026Document · Index
May 1, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Apr 28, 20268-KShareholder vote results· period Apr 23, 2026Document · Index
Apr 27, 20264Statement of changes in beneficial ownership (insider trade)· period Apr 23, 2026Document · Index
Apr 27, 20264Statement of changes in beneficial ownership (insider trade)· period Apr 23, 2026Document · Index

Insider filing activity

64 Form 4 filings appear in JOHNSON & JOHNSON’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations· Companies headquartered in New Jersey

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0000200406 and XBRL company facts. JOHNSON & JOHNSON on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.